In Ig light chain (AL) amyloidosis, cardiac involvement is associated with worse prognosis and increased treatment-related complications. In this retrospective cohort study, we assessed survival, hematologic and cardiac responses to high-dose melphalan and auto-SCT (HDM/SCT) in patients with AL amyloidosis and cardiac involvement, stratified by cardiac biomarkers brain natriuretic peptide and Troponin I, analogous to the Mayo cardiac staging. Forty-seven patients underwent HDM/SCT based upon functional measures; six patients had modified cardiac stage I disease, seventeen had modified cardiac stage II disease and twenty-four had modified cardiac stage III disease. Treatment-related mortality was 4% for all patients and 8% for patients with stage III disease. Three-year survival was 88% and EFS was 47%; these did not differ by stage. By intention-to-treat analysis, 27% of patients achieved a hematologic complete response and 32% a very good partial response, of whom 70 and 45%, respectively, have not required additional therapy at 36 months. Cardiac response was achieved in 53% of patients. We conclude that with appropriate patient selection and a risk-adapted treatment approach, HDM/SCT is safe and effective in patients with AL amyloidosis and cardiac involvement.
INTRODUCTION
Systemic light chain (AL) amyloidosis is a plasma cell dyscrasia producing light chain Igs, which form insoluble amyloid fibrils that deposit in tissues and cause organ failure. The median survival for untreated cardiac AL amyloidosis is 6-9 months from symptom onset. 1 Troponin I (TnI), troponin T (TnT) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) levels are all predictors of survival. 2 An initial prognostic model based on cardiac biomarkers NT-proBNP and troponin T was proposed. 2 Stage I was defined as having no abnormal elevation of cardiac biomarkers and stage III as having two abnormal markers; abnormal levels were defined as NT-proBNP 4332 ng/L and TnT 40.035 mg/L. With high-dose melphalan and auto-SCT (HDM/SCT), the median survival in stage III was only 8.4 months, but was not reached for stage I or II at 20 month follow-up. 3 Recently, serum free light chain (FLC) levels were incorporated and patients were assigned to four stages, with a 4-year estimated survival ranging from 87 to 46% months in stage I and stage IV, respectively, in HDM/SCT. 4 Finally, high-sensitivity TnT is another important baseline prognostic marker, predicting a short median survival for patients with levels above 77 ng/L. 5 Cardiac biomarker staging has been applied to patients treated with novel agents. Even with novel agents, survival in stage III disease remains poor, with a median of only 7.1 months. The poor prognosis is explained in part by the inability of patients to tolerate therapy, with only 34% of stage III patients completing the planned treatment course. 6 Dispenzieri et al. 3 reported that cardiac stage III disease, when compared with stage I and II disease, is associated with a worse survival when undergoing HDM/SCT. Interestingly, elevated NT-proBNP, not symptomatic heart failure, correlated with shorter survival in multi-variate analysis. TnI correlated with treatment-related mortality (TRM). 3 Recently, Madan et al. 7 expanded their analysis to include patients with cardiac involvement that were treated with HDM/SCT. In this retrospective analysis, cardiac biomarker staging was not predictive for OS, but did correlate with a reduced dose of melphalan, which was an independent variable for shorter survival. In this study hypoalbuminemia, defined as serum albumino 2.5 g/dL, correlated with TRM.
Here, we describe the survival and response rates of patients with AL amyloidosis and cardiac involvement who were treated with HDM/SCT in a single center. Cardiac biomarker staging was known before deciding eligibility for or the dose of HDM/SCT. Treatment recommendations were adjusted based upon performance status, New York Heart Association classification and functional measures of exercise capacity, including stair climbing ability and more formal cardio-pulmonary exercise testing.
PATIENTS AND METHODS
Patients with AL amyloidosis undergoing HDM/SCT from January 2008 to December 2011 were studied with the approval of the Institutional Review Board of Boston University School of Medicine Campus. The start date was January 2008, at which time BNP and TnI were routinely collected. For assessment of treatment-related toxicity, the cutoff date was December 2011. For response rates, the cutoff date was May 2011 to allow for 1-year follow-up data. Follow-up status was last updated in June 2012. Informed consent was obtained in accordance with the Declaration of Helsinki. We retrospectively reviewed cases of patients with AL amyloidosis and cardiac 1 involvement who underwent HDM/SCT at this institution. Cardiac involvement was determined by biopsy or echocardiographic abnormalities, as defined by the Consensus Opinion from the 10th International Symposium on Amyloid and Amyloidosis, as well as experienced clinicians using all available clinical and laboratory data. 8 Echocardiographic wall thickness measurements were obtained by established guidelines by a single investigator. 9 Modified cardiac biomarkers were collected prospectively. Cardiac biomarker staging was defined by the presence of a BNP 4100 pg/mL and a troponin I 40.1 ng/mL, with stage I having no elevated biomarkers, stage II having either elevated and stage III having both elevated. TnI is an independent risk factor for survival. 2 BNP was chosen due to a 3.5:1 NT-proBNP: BNP ratio 10 and the observation that BNPo100 pg/mL had a strong negative predictive value for heart failure in patients without amyloidosis. 11 Eligibility criteria for HDM/SCT were confirmed tissue diagnosis, clear evidence of a clonal plasma cell dyscrasia, age 418 years, performance status of p2 using the Southwest Oncology Group criteria, New York Heart Association Class p2, left ventricular ejection fraction 440%, the absence of pleural effusions, room air oxygen saturation 495%, lung diffusion capacity 450%, and supine systolic blood pressure 490 mm Hg, as described in our previous reports. 12 Patients with reduced exercise capacity were assessed by formal cardiopulmonary exercise testing (CPET) and excluded based on the rate of oxygen uptake and exercise oximetry. Hematopoietic stem cells were mobilized with G-CSF at 10-16 mg/kg per day for 3-4 days and a minimum yield of at least 2.5 Â 10 6 CD34 þ cells/kg was required to proceed to HDM. Two patients additionally received plerixafor on demand. Patients received 140-200 mg/m 2 of i.v. melphalan in two divided doses followed by SCT 24-72 h afterwards. The dose of melphalan depended on severity of cardiac disease, performance status and other co-morbidities, as described previously. 12, 13 All patients were assessed for hematologic and cardiac responses at 6 and 12 months post transplant, and annually thereafter. Death was reported by patients' family or physician or confirmed using the Social Security Death Index at http://ssdi.rootsweb.ancestry.com. OS was measured from stem cell infusion to death or last follow-up. TRM was defined as death within 100 days of the stem cell infusion or death during stem cell mobilization and collection. EFS was defined as time from stem cell infusion to initiation of additional chemotherapy for progression of disease or death. Definitions for criteria for hematologic response rates were described previously.
14 Cardiac response was analogous to Palladini et al., 5 but converted NT-proBNP into BNP using a 3.5:1 conversion. To be eligible for cardiac response, patients had a BNP of 4185 pg/dL. Cardiac response was defined as 485 pg/dL and 30% reduction in BNP, progression as 485 pg/dL and 30% increase in BNP, and stable disease if not qualifying for either. Toxicity was measured based on National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3 or 4. The actuarial Kaplan-Meier method was used to estimate OS and EFS. Survival curves were compared using the logrank test. TRM between different groups was compared using Fisher's exact test. Univariate and bivariate analysis were performed using Cox modeling. All analysis was performed using SAS 9.3 (SAS Institute, Cary, NC, USA).
RESULTS

Patient characteristics
Between January 2008 and December 2011, 249 patients with amyloidosis and cardiac involvement were evaluated at the Amyloidosis Center at Boston Medical Center, 241 of whom had both BNP and TnI measured. Fifty-three patients with cardiac involvement underwent treatment with HDM/SCT. Six patients had orthotopic heart transplantation before HDM/SCT and were excluded from analysis. Three patients had concomitant multiple myeloma, defined as 430% plasma cells in the BM or the presence of lytic lesions or hypercalcemia; these patients were included in the analysis. A comparison of baseline clinical and laboratory findings between patients who were and were not treated with HDM/SCT is listed in Table 1 . Patients who were not transplanted were older, had a lower left ventricular ejection fraction (LVEF), lower standing blood pressure, wider interventricular septal thickness, higher BNP and less proteinuria; there was no difference between troponin I and cardiac stage. The baseline clinical and laboratory findings of patients treated with HDM/SCT are listed in Table 2 . All but three (94%) patients had multi-organ involvement: 35 patients (74%) had renal involvement, 7 patients (15%) had gastrointestinal involvement, 8 patients (17%) had peripheral nervous system involvement and 12 patients (26%) had soft tissue involvement. At least half of the patients had modified cardiac stage III disease. Eighteen patients underwent CPET and the lowest rate of oxygen utilization was 12 mL/kg per minute.
Treatment characteristics
Of 47 patients with cardiac involvement and AL amyloidosis, 21 (45%) patients received full FDM at 200 mg/m 2 , while 26 (55%) received modified HDM at 140 mg/m 2 . Full dose melphalan was given to 50% (3/6), 47% (8/17) and 42% (10/24) of patients with modified stage I, II and III disease, respectively. As part of a clinical trial (NCT00790647), nine patients received bortezomib and HDM for conditioning: five with modified HDM and four with full HDM. The median number of stem cells collected was 7.7 Â 10 6 CD34 þ cells/kg (range, 3.1-25.5). The median number of stem cells infused after HDM was 6.0 Â 10 6 CD34 þ cells/kg (range, 3.1-13.9).
Toxicity and survival Median follow-up time was 36 months from D0. TRM for the entire group was 4% (n ¼ 2/47) and 8% (n ¼ 2/24) for modified cardiac Table 3 ). Five patients had an atrial arrhythmia, one of whom died, and two had a ventricular arrhythmia. Patients received modified dose melphalan had higher all grade and grade 3/4 toxicities. Within 1 year of HDM/SCT, three additional patients died: two from disease progression and one from spontaneous intra-abdominal hemorrhage. Of the five patients who died in 1 year, four received modified dose HDM. By Kaplan-Meier survival estimate, OS at 3 years was 89% (95% confidence interval or CI, 75-95), with a trend toward longer survival in stage I or II disease (P ¼ 0.11) (Figure 1) . By KaplanMeier estimate at 1 and 3 years, EFS was 70% (95% CI, 55-82) and 53% (95% CI, 36-69), with a trend toward longer EFS in stage I or II disease ( Figure 1) . No difference in survival was detected based on the dose of melphalan (Figure 2) .
Cox regression univariate analysis for EFS was performed for cardiac biomarker staging, multi-organ involvement, melphalan doses, serum creatinine, serum albumin, BNP and troponin I. None of these variables reached statistical significance. Since stages I/II were the best predictor (hazard ratio 0.59, P ¼ 0.30), bivariate analysis with stage I/II disease was also performed and these factors also did not reach statistical significance. Univariate and bivariate analysis for OS was not performed due to lack of deaths.
Response Hematologic response at 1 year was measurable in 41 patients. By intention-to-treat analysis, 27% achieved a hematologic CR and 32% a very good partial response (VGPR). Seven patients (17%) had hematologic progression despite HDM/SCT. Of those evaluated for hematologic response, 17 (41%) received full dose melphalan and 24 (58%) received modified dose melphalan. There was no difference in response rates between the full and modified Organ-specific cardiac response at 6 and 12 months was measurable in 22 and 19 patients, respectively. At 6 months, 27% had a cardiac response, 36% stable disease and 36% had disease progression. At 12 months, 53% had a cardiac response, 5% had stable disease and 42% had disease progression. At 1 year, a cardiac response was seen in 42% of patients with a hematologic CR or VGPR, compared with only 5% in those who have at most a partial response. Twenty-three percent of patients had at least a 2-mm improvement in interventricular wall thickness.
DISCUSSION
We report a single institution experience of HDM/SCT in patients with AL amyloidosis and cardiac involvement and conclude that with appropriate patient selection, it is safe and effective. Furthermore, modified cardiac biomarker staging did not predict or affect OS or TRM after HDM/SCT. With careful patient selection, OS and TRM were not different between modified cardiac biomarker stage I-II and III disease. This was previously suggested by Madan et al., 7 who reported no increase in TRM with modified stage III cardiac biomarker disease, although it is noteworthy that the Mayo cardiac staging was designed to predict OS, not TRM. TRM following HDM/SCT in this current report was 4%, and was 8% for modified cardiac biomarker stage III disease (P ¼ 0.623). It did not correlate with serum albumin of o2.5 g/dL, which has been demonstrated by Madan et al. 7 We attribute this low TRM to patient selection, optimal pre-and post-transplant supportive care, and the experience of multi-disciplinary team members. Patient selection was dependent upon an objective assessment of functional status, such as exercise oximetry, stair climbing and formal CPET. The effect of exercise oximetry and CPET on TRM and survival is being examined separately and will be reported shortly. Another explanation is that cardiac biomarkers were collected prospectively and were available during evaluation for HDM/SCT, which may have influenced patient selection. The stringency of patient selection is highlighted by the fact that only 20% of patients with AL amyloidosis and cardiac involvement underwent HDM/SCT. Cardiac stage did not differ between these groups, although other markers of cardiac disease, such as BNP, IVS and LVEF, did. Higher rates of TRM have been reported for troponin T40.06 ng/mL and NT-proBNP45000 pg/mL, 15 but neither of these is measured routinely at our institution. The highest BNP in our study was 923 pg/mL, which is significantly lower than the BNP equivalent of an NT-proBNP of 5000 pg/mL. Our stringent entry criteria and evaluation likely excluded those with very significant cardiac involvement.
In this study, median survival was not reached with a median follow-up of 36 months and the 3-year survival was 88%. Of the five deaths, two were treatment related and three were related to amyloidosis. None of the patients died from arrhythmia, heart failure or hypotension, previously common causes of death in cardiac involvement. Longer follow-up will be required to assess long-term outcome in these patients. However, it is intriguing that the dose of melphalan did not affect OS, contrary to our observation in a series of all amyloid patients, including those with cardiac involvement. 13 Median EFS was 36 months and there was a trend toward shorter EFS in stage III cardiac involvement (33 months) compared with stage I and II (not reached). Univariate and bivariate analysis did not show any statistically significant prognostic variables.
Importance of hematologic CR rates has been illustrated in multiple series. In HDM/SCT, hematologic CR correlates with EFS, OS, cardiac response and reduction in cardiac biomarkers. 7, 13 Patients who do not achieve a VGPR or have a less than 90% reduction in serum FLCs exhibit a much worse prognosis. 16, 17 In our series, the hematologic CR rate was 27% by intention-to-treat analysis, which compares with 43% in all evaluable patients with AL amyloidosis treated with HDM/SCT in our previous series. 13 The lower rate of CR can be explained, in part, by the lower rate of full dose melphalan (41%), as the hematologic CR rate is usually higher with full dose melphalan when compared with modified dose (43% versus 24%). 13 Our observation that hematologic response rates are similar in full and modified dose melphalan reflects a sample size bias.
Clinical response with improvement in organ dysfunction can occur following HDM/SCT in patients with AL amyloidosis. Cardiac response occurs in 17-41% with HDM/SCT. 7, 18 In this series, we report a 53% cardiac response. The higher response rate reflects the use of updated cardiac response criteria, which correlated with survival.
14 Previous studies measured cardiac response using echocardiography and New York Heart Association classifications of heart failure. Modified dose melphalan had higher cardiac toxicity in part related to more advanced cardiac involvement and more co-morbidities.
This study has its limitations. First, the Mayo clinic cardiac staging is based on NT-proBNP and TnT, whereas BNP and TnI were used in this study. The use of BNP and TnI has not been validated, but we believe that the staging criteria used in this study is analogous to those of Dispenzieri et al. 2 Univariate Cox regression analysis has shown that TnT had a higher hazard ratio than TnI (2.38 versus 1.74), but both were statistically significant Po0.0001. Therefore, TnI is an independent risk factor for survival in AL amyloidosis. 2 BNP, which has not been validated in amyloidosis with cardiac involvement, differs from NT-proBNP in that the former is a smaller molecule and less sensitive to changes in kidney function. The threshold for TnI was based on Cox regression analysis 2 and the threshold for BNP was chosen due to a 3.5:1 NT-proBNP:BNP ratio 10 and the observation that BNPo100 pg/mL had a strong negative predictive value for heart failure in patients without amyloidosis. 11 Second, this study is underpowered to detect a subtle difference in survival based on cardiac staging. The OS and EFS was not shorter in stage III (P ¼ 0.11 and P ¼ 0.14, respectively), although it could reach statistical significance if more patients are studied.
In summary, HDM/SCT is a safe and effective treatment for selected patients with AL amyloidosis and cardiac involvement, even for some with modified biomarker stage III disease. Patients who do not achieve at least a VGPR should be assessed for additional therapy. As non-transplant regimens are developed and optimized for this high-risk group of patients, randomized studies will be required to compare outcomes between non-transplant and transplant approaches. . These was no difference in survival (P ¼ 0.55) between full and modified doses of melphalan.
